ADHD medication and focus comparison

Methylene blue vs guanfacine: Intuniv, Tenex, ADHD, and safety questions

Compare low-dose oral methylene blue with guanfacine, Intuniv, and Tenex using clinician-safe questions about ADHD care, blood pressure, heart rate, sedation, rebound hypertension, G6PD deficiency, interactions, and pharmacy sourcing.

Educational guideUpdated July 17, 2026

A safer methylene blue vs guanfacine review path

Name the clinical question first: diagnosed ADHD, high blood pressure, new attention symptoms, brain fog, daytime sleepiness, medication side effects, or a general focus or longevity goal.

Identify the exact guanfacine product and methylene-blue product. Record immediate-release versus extended-release, brand or generic name, route, concentration, pharmacy, prescriber, directions, and last-use date.

Bring the current labels and complete medication list to the guanfacine prescriber and pharmacist instead of relying on a nootropic stack, social-media interaction checker, or seller switching chart.

Review blood pressure, pulse, fainting, heart rhythm or conduction history, hydration, sedation, driving, kidney or liver history, mood, G6PD status, anemia, pregnancy context, and every medicine or supplement.

Reject research-use or dye-grade methylene blue, no-prescription guanfacine, guaranteed ADHD or focus claims, abrupt-stop advice, and websites that hide the clinician or dispensing pharmacy.

Direct answer

Methylene blue is not a substitute for guanfacine. Extended-release guanfacine, including Intuniv, is FDA-labeled for ADHD as monotherapy or with a stimulant; immediate-release guanfacine, historically sold as Tenex, has a different hypertension label and is not interchangeable milligram for milligram with the extended-release product. Low-dose oral methylene blue marketed for focus or longevity is off-label or compounded and is not FDA-approved for ADHD. Guanfacine labeling emphasizes low blood pressure, slow heart rate, fainting, sedation, conduction problems, and rebound hypertension after abrupt discontinuation. Current methylene-blue injection labeling separately emphasizes serotonin-syndrome and G6PD-related hemolysis risks. A safe comparison requires the guanfacine prescriber and pharmacist to review the exact formulations, full medication list, blood pressure and pulse history, and reason for considering methylene blue before either product is combined, stopped, or changed.

Different treatment roles

Extended-release guanfacine treats ADHD; oral methylene blue does not

Guanfacine is a central alpha-2A adrenergic receptor agonist. Current extended-release guanfacine labeling lists ADHD treatment as monotherapy and as adjunctive therapy to stimulant medication. MedlinePlus distinguishes long-acting guanfacine used in ADHD care from immediate-release guanfacine used for high blood pressure. FDA-approved methylene-blue injections treat acquired methemoglobinemia. Low-dose oral methylene blue discussed for focus, fatigue, mitochondrial support, or longevity is a different route and an off-label or compounded pathway—not an FDA-approved ADHD treatment, guanfacine alternative, or productivity medicine.

Do not replace, pause, or reduce guanfacine because a post calls methylene blue a natural ADHD medicine, nootropic, mitochondrial enhancer, or non-stimulant alternative.
New or worsening attention problems can reflect sleep loss, sleep apnea, depression, anxiety, thyroid disease, anemia, substance use, medication effects, or another condition that needs diagnosis-first care.
Product identity matters: immediate-release guanfacine and extended-release guanfacine have different labeled uses and pharmacokinetic profiles and should not be treated as interchangeable products.

Blood pressure and sedation

Guanfacine needs vital-sign, fainting, and alertness review

Current Intuniv and extended-release guanfacine labeling warns about dose-dependent decreases in blood pressure and heart rate, orthostatic hypotension, fainting, sedation or somnolence, cardiac-conduction abnormalities, and clinically significant rebound hypertension after abrupt discontinuation. Dehydration, overheating, alcohol, sedating medicines, antihypertensives, and other products that reduce heart rate or blood pressure can change the risk. These are prescriber-managed issues, not reasons to skip, double, stop, taper, or switch a dose without instructions.

Review recent blood pressure and pulse, dizziness on standing, fainting, dehydration, heat exposure, slow heart rate, heart block or rhythm history, kidney disease, and every blood-pressure or heart-rate medicine.
Review sleepiness, driving, work or school safety, alcohol, cannabis, antihistamines, sleep medicines, opioids, muscle relaxants, and other central nervous system depressants.
Do not abruptly stop guanfacine or use a seller-provided taper. The prescribing clinician should provide formulation-specific instructions when a change is medically appropriate.

Interaction boundary

No named shortcut replaces a full medication and product review

A guanfacine label may not name oral methylene blue specifically, but absence from a short interaction list is not proof that an off-label or compounded product is safe to combine. Guanfacine exposure can be affected by medicines that alter CYP3A4 activity, and its blood-pressure, heart-rate, and sedating effects can overlap with other products. Current methylene-blue injection labeling describes methylene blue as a potent reversible monoamine oxidase inhibitor and carries a boxed warning for serious or fatal serotonin syndrome with serotonergic drugs and opioids. Those intravenous-label findings do not create a universal oral-methylene-blue interaction or washout schedule.

Disclose SSRIs, SNRIs, MAOIs, bupropion, buspirone, tricyclics, mirtazapine, linezolid, triptans, opioids, dextromethorphan, stimulants, decongestants, antihypertensives, sedatives, alcohol, cannabis, and nootropic supplements.
Also disclose CYP3A4 inhibitors or inducers, including prescription medicines and grapefruit or St. John’s wort, so the pharmacist can assess the exact guanfacine product and current label.
Do not combine products, copy an internet washout interval, or change either medicine until the relevant prescriber and pharmacist review the route, formulation, concentration, source, timing, and full medication list.

Methylene-blue safety and sourcing

Route, G6PD status, serotonergic medicines, and pharmacy identity matter

Current methylene-blue injection labeling is route-specific and addresses serotonin syndrome, hypersensitivity, G6PD deficiency, and hemolytic anemia. It does not approve low-dose oral methylene blue for ADHD, focus, or guanfacine replacement. Compounded preparations are not FDA-approved finished drug products. Search results may mix licensed care with aquarium or dye products, research chemicals, vague “pharmaceutical grade” liquids, copied stacks, and sellers that omit medication screening.

Review known or possible G6PD deficiency, anemia or hemolysis, dark urine or jaundice, pregnancy or breastfeeding, kidney or liver disease, dye reactions, exact route, and pharmacy source.
Urgent evaluation may be needed for fainting, chest pain, seizure, severe agitation or hallucinations, high fever, marked rigidity, rapidly worsening confusion, severe headache with major blood-pressure symptoms, very slow heart rate with symptoms, dark urine, or jaundice.
Avoid research-use, laboratory, aquarium, industrial, or dye-grade methylene blue and any guanfacine seller that bypasses a prescription, medication review, vital-sign plan, or follow-up.

Patient safety checklist

Questions to ask before comparing methylene blue and guanfacine

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

Am I treating diagnosed ADHD or hypertension, or trying to solve new brain fog, fatigue, sleepiness, anxiety, depression, medication side effects, or a general productivity or longevity goal?

✓

Which exact guanfacine and methylene-blue products, formulations, routes, concentrations, labels, pharmacies, prescribers, directions, and last-use dates apply?

✓

Is the guanfacine immediate-release or extended-release, and has the prescriber confirmed the labeled use rather than treating Tenex, Intuniv, and every generic product as interchangeable?

✓

What are my recent blood pressure and pulse, and have fainting, dizziness, dehydration, slow heart rate, heart conduction history, kidney or liver disease, sleepiness, and driving safety been reviewed?

✓

Have I disclosed every antidepressant, opioid, migraine medicine, cough product, antibiotic such as linezolid, stimulant, decongestant, antihypertensive, sedative, CYP3A4-interacting medicine, alcohol or cannabis product, supplement, and nootropic?

✓

Do G6PD deficiency, anemia or hemolysis history, dark urine or jaundice, pregnancy or breastfeeding, or a prior dye reaction change the methylene-blue discussion?

✓

Who will coordinate the guanfacine prescriber, pharmacist, primary-care or mental-health clinician, and any Peptide12 clinician reviewing low-dose oral methylene blue?

✓

What is the measurable goal, follow-up interval, blood-pressure and pulse plan, alertness plan, side-effect plan, stop rule, and urgent-care threshold?

FAQs

Short answers for patients

Can methylene blue replace guanfacine or Intuniv for ADHD?

No evidence or FDA label supports low-dose oral methylene blue as a guanfacine or Intuniv replacement for ADHD. Do not stop, switch, or reduce guanfacine without the prescribing clinician. Attention symptoms should be reviewed by diagnosis, formulation, response, side effects, sleep, mental health, cardiovascular context, and other possible causes.

Can I take methylene blue with guanfacine?

Do not combine them without coordinated prescriber and pharmacist review. The exact guanfacine formulation, blood pressure, pulse, fainting or sedation history, full medication list, and the methylene-blue route, concentration, source, timing, and reason for use all matter. A label not naming the combination is not proof of safety.

Are Intuniv and Tenex the same as every guanfacine product?

They contain guanfacine, but the formulation and labeled use matter. Intuniv is an extended-release ADHD product; Tenex historically refers to an immediate-release hypertension product. Current labeling says extended-release guanfacine should not be substituted milligram for milligram for immediate-release tablets because their pharmacokinetic profiles differ.

Can I stop guanfacine before trying methylene blue?

Do not stop guanfacine on your own. Current extended-release labeling warns that abrupt discontinuation can cause clinically significant rebound hypertension. The prescriber should provide product-specific instructions if a change is appropriate; an online taper chart is not a safe substitute.

Is oral methylene blue FDA-approved for ADHD or focus?

No. FDA-approved methylene-blue injections treat acquired methemoglobinemia. Low-dose oral methylene blue discussed for focus, fatigue, mitochondrial support, or longevity is off-label or compounded and is not FDA-approved for ADHD, productivity, or guanfacine replacement.

What online seller red flags should I avoid?

Avoid no-prescription guanfacine, research-use or dye-grade methylene blue sold for ingestion, guaranteed ADHD or focus claims, abrupt-stop or copied taper instructions, hidden clinician or pharmacy identity, and sellers without medication, blood-pressure, pulse, interaction, or follow-up screening.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

DailyMed: Intuniv (guanfacine) extended-release prescribing information DailyMed: Guanfacine extended-release prescribing information — published June 2026 MedlinePlus: Guanfacine drug information DailyMed: Methylene blue injection prescribing information — published June 2026 MedlinePlus Genetics: Glucose-6-phosphate dehydrogenase deficiency FDA: Compounding and the FDA — Questions and Answers Peptide12: Methylene blue vs atomoxetine Peptide12: Methylene blue vs Adderall Peptide12: Methylene blue vs Ritalin Peptide12: ADHD and stimulant medication review Peptide12: Methylene blue medication interactions Peptide12: Methylene blue safety guide Peptide12: When in-person care is needed Peptide12: Low-dose oral methylene blue Peptide12: How online peptide therapy works